Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2014-04-22 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 152.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a specific quarter ended 31 March 2014 and includes substantive financial data and analysis for that period. The length of the document (7357 characters) and the detailed financial content indicate it is a comprehensive quarterly financial report rather than a brief announcement or certification. The presence of actual financial statements and cash flow details aligns with the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-04-22 English
Change of Director's Interest Notice (NE) 2 pages 50.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is about 4013 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2014-04-16 English
Imugene Allowed Israel Patent for Cancer Vaccine 1
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Imugene Limited has received an Intention to Grant communication from the Israeli Patent Office for its cancer vaccine HER-Vaxx. It discusses the patent status and some background on the vaccine and company but contains no financial data, regulatory filings, or detailed report content. It is not an annual report, earnings release, or any financial or governance filing. It is an announcement related to intellectual property rights and patent status, which does not fit into any of the specific financial or corporate filing categories. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other categories.
2014-03-23 English
IMU Commences FDA IND Process for Gastric Cancer vaccine 2 pages 148.4KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Imugene has commenced the FDA IND (Investigational New Drug) process for a gastric cancer vaccine. It contains no financial data, no regulatory filings, no meeting materials, no voting results, no management or board changes, no earnings or annual reports, and no detailed financial or operational analysis. The content is primarily a corporate announcement about a regulatory process initiation related to drug development. It does not fit into any of the specific financial or corporate filing categories such as Annual Report, Earnings Release, or Management Reports. Given the nature of the announcement and the lack of financial or regulatory filing content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2014-03-16 English
Half Yearly Report and Accounts 23 pages 736.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D For the Half Year Ended 31 December 2013' and contains detailed financial statements including Consolidated Statement of Profit or Loss, Statement of Financial Position, Statement of Changes in Equity, and Cash Flows for the half year period ending 31 December 2013. It includes Directors' Report, Auditor's Independence Declaration, and notes to the financial statements. The presence of comprehensive financial data and analysis for a half-year period indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial statements, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-02-26 English
Imugene Investor Update 6 pages 2.7MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Update Issue 1' and is an extensive newsletter-style update from Imugene Ltd, a biopharmaceutical company. It provides detailed information about the company's acquisition, product pipeline (HER-Vaxx cancer vaccine), scientific background, clinical trial plans, and board changes. The content is focused on updating investors about company progress, scientific rationale, and upcoming clinical trials rather than presenting formal financial results or regulatory filings. There are no financial statements, earnings highlights, or regulatory certifications. The document is a detailed investor communication but not a formal investor presentation slide deck or earnings call transcript. Given the nature of the document as a periodic update to investors with detailed company and product information, it best fits the category of an Investor Presentation (IP). The length and detail support this classification rather than a brief factsheet or a regulatory announcement.
2014-02-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.